Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 14507
Country/Region: Zambia
Year: 2016
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USDOD
Total Funding: $5,142,304 Additional Pipeline Funding: $1,512,399

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $200,000
Care: TB/HIV (HVTB) $400,000
Care: Pediatric Care and Support (PDCS) $40,000
Strategic Information (HVSI) $287,601
Health Systems Strengthening (OHSS) $400,000
Testing: HIV Testing and Counseling (HVCT) $150,000
Treatment: Adult Treatment (HTXS) $3,030,191
Treatment: Pediatric Treatment (PDTX) $634,512
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 1,000
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 1,539
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 18,930
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 14,431
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 35,900
HTS_TST Service Delivery Point (Facility): Index testing 2017 4,308
HTS_TST Service Delivery Point (Facility): Inpatient 2017 718
HTS_TST Service Delivery Point (Facility): Other PITC 2017 7,180
HTS_TST Service Delivery Point (Facility): Outpatient 2017 1,436
HTS_TST Service Delivery Point (Facility): Pediatric 2017 1,436
HTS_TST Service Delivery Point (Facility): PMTCT 2017 5,744
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 718
HTS_TST Service Delivery Point (Facility): VCT 2017 14,360
HTS_TST Sum of Aggregated Age/Sex <15 2017 2,539
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 33,361
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 35,900
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 310
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 260
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 4,018
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,404
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,140
PMTCT_ART New on ART 2017 660
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 7,606
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 332
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 1,000
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 69
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 2
PMTCT_EID Sum of Infant Age disaggregates 2017 1,332
PMTCT_STAT By: Known positives at entry 2017 1,800
PMTCT_STAT By: Number of new positives identified 2017 660
PMTCT_STAT Number of new ANC and L&D clients 2017 7,935
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 7,606
PMTCT_STAT Sum of Positives Status disaggregates 2017 2,460
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 85
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 96
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 183
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 183
TB_SCREENDX [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 183
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only 2017 73
TB_SCREENDX [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 110
TB_SCREENDX Screen Results: Screened Positive for TB 2017 183
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 638
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 564
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 18,141
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 14,219
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 33,562
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 12
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 153
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 14
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 251
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 430
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 430
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,493
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,539
TX_CURR Aggregated Age/Sex: 15+ Female 2017 23,358
TX_CURR Aggregated Age/Sex: 15+ Male 2017 17,362
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 43,752
TX_CURR Sum of Aggregated Age/Sex <15 2017 3,032
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 40,720
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 43,752
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 279
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 234
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 3,616
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 2,164
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 6,293
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 6,293
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 10,488
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 10,488
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 1,093
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 1,139
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 4,751
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,505
TX_PVLS Numerator: Indication: Routine 2017 2,098
TX_PVLS Numerator: Indication: Targeted 2017 8,390
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 1,093
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 1,139
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 4,751
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,505
TX_PVLS_den Denominator: Indication: Routine 2017 2,098
TX_PVLS_den Denominator: Indication: Targeted 2017 8,390
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 328
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 276
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,811
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,084
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 3,499
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 3,499
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 328
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 276
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,811
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,084
Cross Cutting Budget Categories and Known Amounts Total: $1,075,000
Human Resources for Health $500,000
Motor Vehicles: Purchased $575,000